ClinicalTrials.gg
CompletedNCT00005012Updated Jun 24, 2005

Safety and Effectiveness of PEG-Intron in HIV-Infected Patients

A Phase 2 interventional study of Peginterferon alfa-2b in HIV Infections, sponsored by Schering-Plough. Completed at 22 sites in 2 countries. Open to participants aged 0 Years and older. Per ClinicalTrials.gov, last updated 2005-06-24.

Sponsored by Schering-Plough (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
250
Ages
0 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 75 studies in HIV Infections by Merck & Co., Inc — 1 open to participants now, 2 under way, 1 of them phase 3. HIV Infections · Merck & Co., Inc.

Enrollment
26th of 66
250 · median 163
Started
2000
the only one that year
Phase 2
25 of 75
1 open now
Registered
24th of 75
by date

Among the 75 studies in HIV Infections by Merck & Co., Inc, this one is the 26th largest by enrollment of the 66 interventional ones that give a count, is the only one that started in 2000, is one of 25 in phase 2, and was the 24th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

1 of the 75 studies in HIV Infections by Merck & Co., Inc is open now. Recruiting first, the newest first:

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 0 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in HIV Infections by Merck & Co., Inc, or all of them as a file.
02

Study summary

The purpose of this study is to see if it is effective to give PEG-Intron (PEG-IFN) to HIV-infected patients who are not doing well with their current anti-HIV drug combination (HAART).

Read the detailed description

At entry, patients undergo HIV genotypic/phenotypic analysis. Patients continue their current antiretroviral regimen but are randomized to receive one of four doses of PEG-IFN or PEG-IFN placebo administered subcutaneously once per week until results of HIV genotyping/phenotyping are available (approximately 4 weeks). Patients who respond with a 0.5 log or greater decrease in HIV RNA at Week 4 have optimized HAART added to their ongoing PEG-IFN regimen and are followed for 24 weeks in an observational study.

03

Conditions studied

  • HIV Infections

Browse trials for

Keywords

  • Interferon Alfa-2b
  • Lymphocyte Transformation
  • CD4 Lymphocyte Count
  • RNA, Viral
  • Virus Inhibitors
  • Anti-HIV Agents
  • Viral Load
04

Who can participate

Ages eligible
0 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients may be eligible for this study if they:

  • Have levels of more than 2000 copies/ml.
  • Have failed their current HAART (had a significant increase in their HIV levels with HAART).
  • Have a greater than 200 cells/microL.
  • Have had more than 6 months of HAART.
  • Have been on their current HAART for at least 6 weeks.
  • Agree to use an effective method of during the study.

Exclusion criteria

Exclusion Criteria

Patients will not be eligible for this study if they:

  • Have a history of a serious mental disorder.
  • Are allergic to interferons.
  • Are pregnant or breast-feeding.
  • Are taking certain medications such as ribavirin, hydroxyurea, and ganciclovir.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Enrollment
250 participants

Interventions

06

Study locations

22 sites
  • East Bay AIDS Ctr
    Berkeley, California 94705, United States
  • Georgetown Univ Med Ctr
    Washington, District of Columbia 20007, United States
  • Dupont Circle Physicians Group
    Washington, District of Columbia 200091104, United States
  • IDC Research Initiative
    Altamonte Springs, Florida 32701, United States
  • Duval County Health Department
    Jacksonville, Florida 32206, United States
  • Univ of Miami School of Medicine
    Miami, Florida 33136, United States
  • Infectious Diseases Associates
    Sarasota, Florida 34239, United States
  • Piedmont Physicians at Vinings
    Atlanta, Georgia 30339, United States
  • TRIAD Health Practice
    Chicago, Illinois 60657, United States
  • Univ of Maryland Institute of Human Virology
    Baltimore, Maryland 212011192, United States
  • New England Med Ctr / Div of Geo Med & Infect Disease
    Boston, Massachusetts 02111, United States
  • Regions Hosp
    St. Paul, Minnesota 55101, United States
  • Washington Univ
    St. Louis, Missouri 63110, United States
  • Southwestern New Jersey AIDS Clinical Trials
    Camden, New Jersey 08103, United States
  • East Orange Veterans Administration Med Ctr
    East Orange, New Jersey 07018, United States
  • Beth Israel Med Ctr
    New York, New York 10003, United States
  • Univ Hosps of Cleveland
    Cleveland, Ohio 44106, United States
  • MCP Hahnemann Univ
    Philadelphia, Pennsylvania 19102, United States
  • Philadelphia FIGHT
    Philadelphia, Pennsylvania 19107, United States
  • Amelia Ct Clinic
    Dallas, Texas 75235, United States
  • Joseph C Gathe
    Houston, Texas 77004, United States
  • San Juan VAMC
    San Juan, 009265800, Puerto Rico
07

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2000 and a completion of Sep 2000. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2000
First posted
Aug 31, 2001
Start
Mar 2000
Completion
Sep 2000
Last update
Jun 24, 2005
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Jun 24, 2005, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00005012
Lead sponsor
Schering-Plough
First posted
Aug 31, 2001
Start date
Mar 2000
Completion
Sep 2000
Last update
Jun 24, 2005
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2000. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Peginterferon alfa-2b

Start the discussion